Miruvor
Sign up
The short answer

What studies of ivabradine found

17papers on ivabradine
192people in 7 studies testing ivabradine alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

4 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

6 outcomes rated · see each below

Preventing long COVID: B May help

Based on the strongest evidence, the randomised trial (low certainty), for autonomic symptoms.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, ivabradine might help some people, but research can’t show it yet. For long COVID and ME/CFS studied together, ivabradine might help some people, but research can’t show it yet. For preventing long COVID, ivabradine may help, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 17 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Ivabradine · Preventing long COVID is hereB
    May helpImprovement, low certainty
  3. Ivabradine · Long COVID is hereIvabradine · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Autonomic symptoms5 studies · 131 people took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group5 studies · 131 people with results

Autonomic symptoms improved.

The evidence is very uncertain about the effect of ivabradine on autonomic symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 5 studies
  1. Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study. (2023)

    People in the study
    55 in the study
    Dose
    5 mg, twice daily
    Outcome
    HRV time-domain parameters (SDNN, rMSSD) Holter electrocardiogram (ECG)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA (2022)

    People in the study
    27 in the study
    Dose
    5 mg, twice a day, during 8 weeks
    Outcome
    Heart rate (ЧСС) on 24-hour Holter monitoring before vs after 8 weeks
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Сardiac manifestations of post-COVID syndrome: tachycardia (2023)

    People in the study
    48 in the study
    Dose
    —
    Outcome
    heart rate control
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. COVID-19 utáni nem adekvát sinustachycardia, terhelési intolerancia kezelése ivabradinnal (2021)

    People in the study
    —
    Dose
    2×5 mg, Napi 2×5 mg
    Outcome
    Nyugalmi szívfrekvenciája
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  5. Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience (2021)

    People in the study
    1 in the study
    Dose
    2,5 мг 2 р/сут (5 мг/сут), в последующем – с увеличением дозы до 5 мг 2 р/сут (10 мг/сут) через 2 нед лечения
    Outcome
    уменьшение ЧСС и ощущения сердцебиения
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 27 people took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (27 in all); not all results were tested against chance.

Studies with no comparison group27 in the study · 8 weeks of treatment; measurements 'Через 8 недель' · 5 mg, twice a day, during 8 weeks

Low mood or anxiety improved.

The evidence is very uncertain about the effect of ivabradine on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)
  • Not all results were tested against chance
See the 1 study
  1. EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA (2022)

    People in the study
    27 in the study
    Dose
    5 mg, twice a day, during 8 weeks
    Outcome
    Perfection of mood
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms2 studies · 56 people took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group2 studies · 56 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of ivabradine on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study. (2023)

    People in the study
    55 in the study
    Dose
    5 mg, twice daily
    Outcome
    significant improvement of the symptoms within 7 days of ivabradine therapy
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience (2021)

    People in the study
    1 in the study
    Dose
    2,5 мг 2 р/сут (5 мг/сут), в последующем – с увеличением дозы до 5 мг 2 р/сут (10 мг/сут) через 2 нед лечения
    Outcome
    существенное улучшение самочувствия с регрессом беспокоящих ее симптомов
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 27 people took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (27 in all); not all results were tested against chance.

Studies with no comparison group27 in the study · 8 weeks of treatment; measurements 'Через 8 недель' · 5 mg, twice a day, during 8 weeks

Quality of life improved.

The evidence is very uncertain about the effect of ivabradine on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)
  • Not all results were tested against chance
See the 1 study
  1. EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA (2022)

    People in the study
    27 in the study
    Dose
    5 mg, twice a day, during 8 weeks
    Outcome
    Increase of the quality of life
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Both together

Symptoms

Autonomic symptoms1 study · 1 (few people) person took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of ivabradine on autonomic symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    peak heart rate when walking on cromolyn
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Pain improved.

The evidence is very uncertain about the effect of ivabradine on pain in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    remaining symptoms at one year
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person took ivabradine Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Too little to say about cognition (brain fog).

Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took ivabradine Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Too little to say about fatigue.

Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of ivabradine on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    energy and overall function on naltrexone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · over 30 months (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of ivabradine on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    symptom improvement over 30 months
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Preventing long COVID

Symptoms

Autonomic symptoms1 study · 60 people took ivabradine Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (90 in all).

The randomised trial90 randomised · 24 нед · 5 мг/сут

Autonomic symptoms improved more than in the comparison group.

Ivabradine may reduce autonomic symptoms later, when given during acute COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (90 in all)
See the 1 study
  1. Comparative efficacy of ivabradine and beta-blockers in the treatment of tachycardia in patients after COVID-19 (2022)

    People in the study
    90 randomised
    Dose
    5 мг/сут
    Outcome
    HR at visit H4, between groups
    Effect
    better (not tested)
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning1 study · 60 people took ivabradine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (90 in all).

The randomised trial90 randomised · 24 нед · 5 мг/сут

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of ivabradine on daily functioning later, when given during acute COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (90 in all)
See the 1 study
  1. Comparative efficacy of ivabradine and beta-blockers in the treatment of tachycardia in patients after COVID-19 (2022)

    People in the study
    90 randomised
    Dose
    5 мг/сут
    Outcome
    increase in physical activity over 24 weeks, between groups тест шестиминутной ходьбы (ТШХ)
    Effect
    better (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Quality of life1 study · 60 people took ivabradine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 90 people found no clear difference; a small benefit can't be ruled out.

The randomised trial90 randomised · 24 нед · 5 мг/сут

No clear difference in quality of life.

The evidence is very uncertain about the effect of ivabradine on quality of life later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 90 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Comparative efficacy of ivabradine and beta-blockers in the treatment of tachycardia in patients after COVID-19 (2022)

    People in the study
    90 randomised
    Dose
    5 мг/сут
    Outcome
    quality of life by VAS at visits, between groups 100-балльная визуальная аналоговая шкала (ВАШ)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Side effects

Stopping because of side effects2 studies
Side effects studies reported2 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue1 study
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    5 mg at the start in most studies

  2. 2Top dose

    Most often 5 mg (3 of 5 studies)

All papers

  1. Comparative efficacy of ivabradine and beta-blockers in the treatment of tachycardia in patients after COVID-192022 · randomised trial · 90 randomised
    Summary

    Researchers assessed heart rate, exercise tolerance and quality of life after acute COVID-19. This randomized comparative study included 90 patients discharged from a university hospital: 60 in the main group and 30 in the control group. The main group received standard therapy plus ivabradine, starting at 5 mg/day, alone or with beta-blockers; the control group received standard therapy with beta-blockers. Follow-up was 24 weeks. Outcomes included heart rate, the six-minute walk test and a 100-point visual analogue quality-of-life scale. Heart rate at H4 was 71,2±4,1 vs 73,9±5,1 bpm (p=0,015), and at H24 68,9±3,5 vs 70,6±8,4 bpm (p=0,035), with lower values in the ivabradine group. Physical-activity increase over 24 weeks was 80 (60; 135) vs 65 (40; 100) (p=0,017), but no significant between-group six-minute walk test differences were found at each visit. Quality-of-life increase was 35 (27; 45) vs 30 (26; 36) points (p=0,03; Figure 3 note gives p=0,005), while between-group VAS differences at visits were not significant. At H24, BP ≤110/70 mm Hg was recorded in 15 (25%) main-group and 12 (40%) control-group patients; serious adverse events were absent, and all patients completed H24.

  2. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  3. Сardiac manifestations of post-COVID syndrome: tachycardia2023 · no comparison group · 48 in the study
    Summary

    This study asked whether post-COVID tachycardia occurs in apparently healthy patients and whether ivabradine affects it. The authors examined 48 patients who had no comorbid pathology and were assessed 12 or more weeks after COVID-19. All patients included in the study were diagnosed with post-COVID tachycardia syndrome against a background of autonomic imbalance with predominance of sympathetic activity and deterioration in quality of life. Ivabradine was the treatment under study; dose, route, schedule and treatment duration were not reported. There was no comparison group, and the text does not report randomisation, blinding, or a follow-up period. The study reports a positive effect of ivabradine on heart rate control. The authors also conclude that ivabradine is able to control heart rate and level the manifestations of post-COVID tachycardia syndrome. Harms, side effects, withdrawals, and stopping treatment were not reported. The authors state no limitations in the supplied text. Because the report gives no analysed number, no between-group comparison, and no numerical heart-rate data, the summary cannot describe the size of any change, any difference, or any patients who worsened or stopped treatment.

  4. Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study.2023 · no comparison group · 55 in the study
    Summary

    This single-center prospective observational study enrolled 55 patients diagnosed with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) after exclusion of anemia, thyroid dysfunction, and pheochromocytoma. There was no comparison group: all patients received ivabradine 5 mg twice daily, and a follow-up Holter electrocardiogram was done after 7 days with re-assessment of patients' symptoms, heart rate, and heart rate variability parameters. The number analysed was not reported. 78% of the patients reported significant improvement of the symptoms within 7 days of ivabradine therapy. Comparing 24-hour heart rate and heart rate variability before and after ivabradine therapy, 24-hour heart rate (minimum, average, and maximum) was significantly lower (p<0.0001, =0.001, <0.0001 consecutively). There was a significant difference in heart rate variability time-domain parameters (SDNN, rMSSD) (p<0.0001), while there was no difference in frequency-domain parameters (LF, HF) (p=0.51, 0.44 consecutively). Side effects, harms and withdrawals were not reported, and the authors state no limitations.

  5. EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA2022 · no comparison group · 27 in the study
    Summary

    This single-centre trial asked whether ivabradine (Coraxan) would help post-COVID postural orthostatic tachycardia syndrome. It enrolled 27 patients aged 19 to 69 years (16 men, 11 women) at the Kutaisi referral hospital who presented after acute COVID-19. All 27 received ivabradine 5 mg twice a day per os for 8 weeks. There was no comparison group; outcomes were examined before and after treatment in the same patients, so no between-group difference can be reported. Assessments included 24-hour Holter monitoring, echocardiographic EF, EDV and ESV, and clinical reports of heart palpitation, quality of life, mood and tolerability. The paper reports a significant decrease in heart rate on Holter monitoring (p<0.05). It also reports that EF, EDV and ESV improved, and that heart palpitation decreased, quality of life increased and mood improved. No side effects were reported in any patient during treatment. The text does not report any patients who worsened or stopped treatment; withdrawals are not reported. The authors' conclusion is given below. The supplied text does not state explicit limitations; the author says future prospects are based on literature data and her own clinical experience.

  6. COVID-19 utáni nem adekvát sinustachycardia, terhelési intolerancia kezelése ivabradinnal2021 · no comparison group
    Summary

    This single case report describes a 36-year-old primary school teacher with post-COVID-19 inappropriate sinus tachycardia and exercise intolerance, treated with ivabradine 2×5 mg daily; follow-up was at 3 hét múlva. There was no comparison group. Baseline resting ECG showed sinus rhythm around 100/min; Holter showed mean frequency 90/min, but during exertion (hurrying to school) inappropriate sinus tachycardia of 180/min with dyspnoea occurred. After ivabradine, resting heart rate decreased significantly; control Holter mean sinus frequency fell to 79/min. The authors report a 10/min fall in daily average frequency, cessation of exercise-related sinus tachycardia above 180 and its symptoms, and a 25/min reduction in exercise frequency, although exercise was not standardized. The frequency histogram showed morning exertion still present but smaller. Harms, withdrawals and side effects are not reported. The authors state that there is no causal treatment for these symptoms, that both drug use is off-label, and that exercise was not standardized. They conclude that it is understandable why they chose ivabradine for symptomatic sinus tachycardia.

  7. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · case report · 1 in the study
    Summary

    This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.

  8. Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience2021 · case report · 1 in the study
    Summary

    This paper reports a single case of a 74-year-old woman after COVID-19 who had post-COVID syndrome with tachycardia. She was treated with ivabradine 2.5 mg 2 р/сут (5 мг/сут), with the dose increased to 5 mg 2 р/сут (10 мг/сут) after 2 weeks of treatment; treatment lasted 1 month. There was no comparison group and the report was not randomised. The case recorded heart rate on ECG, palpitations and well-being. By the time of dose titration, the text reports improvement with reduction in heart rate and in the sensation of palpitations. At 1 month of treatment, ECG showed heart rate reduced to 60 уд/мин; before treatment ECG showed sinus tachycardia at 100 уд/мин. The patient also reported substantial improvement in well-being with regression of the symptoms that bothered her. The report states that ivabradine treatment was not accompanied by adverse effects. The authors do not state a limitation for this single case.

  9. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine2007 · case report · 1 in the study
    Summary

    This paper reports one patient with chronic fatigue syndrome/myalgic encephalomyelitis who was diagnosed with postural orthostatic tachycardia syndrome (POTS). She was referred to a Tertiary referral Cardiovascular Investigation unit. The paper states her fatigue score, measured by Fatigue Impact Score (FIS) (range 0–160), was 102 and her orthostatic grading scale (OGS) 19 (range 0–20). She was unable to tolerate beta-blockers (asthma) and verapamil (nausea). Despite conservative, non-pharmacologic treatment including volume expansion, her symptoms persisted. The sinus node blocker ivabradine was given at a dose of 2.5 mg twice daily and subsequently 5 mg twice daily. The paper reports 'dramatic improvements in subjective and objective symptomatology (FIS 52, OGS 9)' in line with 'a reduction in heart rate on standing (Figure 1B)'. There was no comparison group; the report compares the patient before and after treatment. The paper does not report worsening or stopping of ivabradine. The authors state: 'This case highlights the potential for the sinus node blocker ivabradine in the treatment of resistant POTS. Use of this medication appears to not only improve tachycardia but also symptomatology, including fatigue. A randomised controlled trial is needed.' The paper gives no duration of treatment, no follow-up period, and no numerical heart-rate values. The authors state the limitation that 'A randomised controlled trial is needed.'

  10. Successful Ivabradine Use Throughout Pregnancy for Postural Orthostatic Tachycardia Syndrome: A Case Report with Reassuring Maternal-Fetal Outcomes2026 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes one 35-year-old gravida 2 para 1 woman with long-COVID postural orthostatic tachycardia syndrome (POTS) who had recurrent emergency department visits and cardiac intensive care admissions for orthostatic palpitations. During her second pregnancy she continued all pharmacologic therapies from preconception through delivery at 38 weeks 5 days: ivabradine 12.5 mg twice daily, propranolol 40 mg 4 times daily, midodrine 15 mg 3 times daily, methyldopa 125 mg nightly, and extended-release nifedipine 30 mg once daily. The report compares her course with her first pregnancy, when cardiac medications were discontinued. Enhanced fetal surveillance included serial nonstress testing, growth studies and fetal Dopplers. Fetal assessments were reassuring throughout gestation, with no evidence of fetal bradycardia, arrhythmia or structural abnormalities, and no evidence of sustained bradycardia or fetal growth restriction. She reported improved symptom control and functional capacity compared with her first pregnancy. At 38 weeks 5 days' gestation an elective repeat low-transverse caesarean delivery occurred without complication; a healthy female neonate was delivered with Apgar scores of 9 and 9, and cord blood gases, newborn examination and standard neonatal screening results were normal. The authors state the polypharmacy confounds attribution of outcomes solely to ivabradine and that maternal hemodynamic data are not presented.

  11. Patient-Centered Paradigm for Managing Autonomic Long COVID Symptoms During Sports and Exercise.2023 · combination: given with other treatments · 1 in the study
    Summary

    The report describes 1 patient, a healthcare worker exposed before vaccination, with post-COVID-19 dysautonomia symptoms during sports and exercise. The abstract states the patient had postural orthostatic tachycardia plus exertional tachycardia, with postexertional fatigue, beginning a few weeks after testing positive for COVID-19. The report is not a comparison group study and does not report randomisation. The patient received a novel regimen of "basal-dose" ivabradine plus very low-dose metoprolol according to an exertional "sliding scale"; the duration is not reported. Recommended nonpharmacological and pharmacological interventions were poorly tolerated before this regimen. The reported outcome was whether symptoms were managed to an acceptable level for work and recreation; the abstract says the regimen managed symptoms to that level. No numerical symptom scores, follow-up time, or analysed sample size are reported. Harms are limited to the statement that recommended interventions were poorly tolerated; no counts, withdrawals, or attribution to the novel regimen are reported. The abstract does not state study limitations.

  12. Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis examined ivabradine in POTS, including classic, pediatric, hyperadrenergic, and post-COVID-19 subgroups. PubMed, Embase, and the Cochrane Library were searched through August 2025; registration was PROSPERO CRD420251073600. Nine studies involving 245 patients were included; eligible studies were randomized controlled trials, observational studies, and case series. The duration of treatment was not reported, and the review reports no comparison group. Outcomes were standing and supine heart rate, symptom burden, quality of life, and adverse events. Ivabradine significantly reduced standing heart rate (-18.5 bpm; 95% confidence interval -23.3 to -13.8) and supine heart rate (-9.7 bpm; 95% confidence interval -13.4 to -6.1). Symptom improvement, particularly palpitations, lightheadedness, and exercise intolerance, was consistently reported across the subgroups. Adverse events were infrequent and mild, most commonly transient visual disturbances, with no reports of severe bradycardia or hypotension. The authors state that evidence is limited by small, heterogeneous, predominantly observational studies and call for large, multicenter randomized controlled trials.

  13. Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic.2024 · systematic review
    Summary

    This systematic review asked whether oral medications for POTS have evidence, including in PASC-associated POTS. The search was conducted through 6 April 2024 and included 32 studies of oral medications; treatment durations varied across studies. The review compared medication arms with placebo or active comparators where available and summarized symptomatic response and change in positional heart rate variability. For PASC-associated POTS, ivabradine had 78.18% treatment success versus 72.45% in pooled non-COVID studies, while a beta-blocker had 59.38% versus 65.12%. In placebo comparisons, midodrine had a treatment success ratio of 0.89 versus 0.53, metoprolol 0.58 versus 0.53, and ivabradine SF-36 physical functioning change was 11.8 versus 2.5. In active comparisons, bisoprolol and propranolol endpoints were largely similar, and adding pyridostigmine did not significantly improve symptom scores. The review reports limitations including only English-language inclusion, lack of standardized symptom scoring and treatment success definitions, unclear randomization/blinding in several RCTs, and few long-term RCTs. No worsening, withdrawal, or side-effect counts were reported in the recorded data.

  14. Pharmacological and non-pharmacological management of long COVID.2026 · review
    Summary

    This narrative review synthesized current evidence on non-pharmacological, pharmacological and probiotic management of long COVID, searching Google Scholar and PubMed for peer-reviewed articles "published up to January 2025"; the authors state that no standardized protocols exist. Reported non-pharmacological data included an online-guided 3-month exercise intervention in 62 patients with post-COVID syndrome that "demonstrated benefits in terms of physical performance," although "overall exercise capacity and quality of life did not improve significantly," and a retrospective study of 86 individuals with post-COVID-19 syndrome in which "patients with high adherence to pacing experienced significantly greater recovery and symptom improvement compared to those with low or moderate adherence." In a randomized, double-blind, placebo-controlled, multicenter trial of 200 participants, "By day 14, fatigue resolution was significantly higher in the intervention group compared to the placebo group (91% vs. 15%)," and "The supplements were well tolerated, with no adverse effects reported." In one study of 38 participants, 19 were given VSL#3 and 19 received a placebo, with "Significant improvement in physical functioning, a decrease in fatigue, and alleviation of gastrointestinal problems" in the probiotic group, while "there were no discernible improvements in the symptoms of somatization, anxiety, depression, or performance." In 36 individuals, after 12 weeks of low-dose naltrexone plus NAD+, "fatigue scores were considerably reduced"; "The iontophoresis patches were associated with only mild, short-lived skin irritation in 25% of patients."

  15. Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
    Summary

    This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.

  16. A Scoping Review of Pharmacological Management of Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2021.2022 · review
    Summary

    This scoping review asked whether medical literature supports or refutes medications to treat postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC), or long-COVID, meaning signs and symptoms that persist after the acute phase. PubMed, EMBASE, Web of Science, and gray literature sources were searched for any study of medication use for PASC. The review included Fifty-two records in final analysis from an initial 3524 records found. The recorded data do not report participant numbers, follow-up duration, a comparison group, randomisation, or harms for this review. Treatments were pharmacological management of PASC in general; no specific drug, dose, or duration is recorded here. The authors state that there is limited, but evolving, literature on medication treatment for PASC. No patient-level results, side-effect counts, or withdrawals are recorded. The stated limitation is the limited, but evolving, literature on medication treatment for PASC.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime